Thursday, February 2, 2023
Home Health Care FDA Alerts Health Care Providers to Stop New Implants of Certain Ventricular...

FDA Alerts Health Care Providers to Stop New Implants of Certain Ventricular Assist Device System

For Fast Launch:

The U.S. Meals and Drug Administration is alerting well being care suppliers to now not implant end-stage coronary heart failure sufferers with Medtronic’s Heartware Ventricular Help System (HVAD) System because of a rising physique of observational medical comparisons that demonstrates a better frequency of neurological hostile occasions and mortality related to the system when in comparison with different commercially obtainable units, in addition to complaints that the inner pump might delay or fail to restart.

Medtronic is stopping the distribution and sale of the HVAD System and has issued an Pressing Medical System Communication Notification Letter requesting physicians to cease new implants of the gadget. This motion comes after the corporate acquired over 100 complaints involving delay or failure to restart of the HVAD pump, together with stories of 14 affected person deaths and 13 circumstances the place an explant was crucial. In line with Medtronic, there are roughly 2,000 sufferers within the U.S. implanted with the gadget and 4,000 worldwide.

The FDA is advising well being care suppliers to comply with the directions offered within the Medtronic Notification Letter, together with stopping new implants of the Medtronic HVAD System; utilizing another, such because the Abbott Heartmate 3 Left Ventricular Help System (LVAS); and advising sufferers who’ve the HVAD System to proceed regular use of gadget elements and to contact the corporate for alternative objects, corresponding to controllers, batteries, AC/DC adapters and carrying case. As well as, Medtronic’s Notification Letter states that suppliers ought to inform sufferers that elective gadget explant is just not advisable, and selections about eradicating the HVAD pump must be made on a case-by-case foundation, with cautious consideration of the affected person’s medical situation and surgical dangers.

“The FDA’s highest precedence is affected person well being and security. We’ve been fastidiously monitoring the hostile occasions related to this gadget and assist its elimination from {the marketplace}. The FDA is working carefully with each Medtronic and Abbott to make sure affected person care is optimized throughout this transition interval and that there’s an sufficient provide of units obtainable to offer this affected person inhabitants with choices for end-stage coronary heart failure remedy,” mentioned Bram Zuckerman, M.D., director of the Workplace of Cardiovascular Units within the FDA’s Middle for Units and Radiological Well being. “The FDA’s alert is designed to rapidly inform well being care suppliers of this essential info in order that sufferers with the present HVAD System proceed to obtain acceptable care and administration. The FDA is dedicated to facilitating the event of secure and efficient units that may present sufferers residing with the devastating situation of end-stage coronary heart failure with the chance for improved high quality of life.”

The Medtronic HVAD System was first authorised for industrial use within the U.S. in November 2012. It’s at the moment authorised as a bridge to coronary heart transplantation in sufferers who’re susceptible to dying from end-stage left ventricular coronary heart failure, for coronary heart tissue restoration and as vacation spot remedy in sufferers for whom a coronary heart transplant is just not deliberate. On the time of approval, the HVAD System was in comparison with one other commercially authorised left ventricular help gadget, and it was decided that the information supported that the possible advantages of the HVAD System outweighed the possible dangers. The gadget is used to deal with sufferers with end-stage coronary heart failure who haven’t responded to medical administration, and the authorised HVAD System labeling features a record of all doable dangers related to the gadget.

Medtronic’s choice to cease the sale and distribution of the HVAD follows the corporate’s voluntary recall of a subset of the HVAD pumps in December 2020. The FDA will proceed to watch hostile occasions related to the HVAD System and preserve well being care suppliers and the general public knowledgeable as new or extra info turns into obtainable.

The FDA encourages well being care professionals and sufferers to report hostile occasions or security issues with the Medtronic HVAD System to FDA’s MedWatch Antagonistic Occasion Reporting program.


Associated Info



The FDA, an company throughout the U.S. Division of Well being and Human Companies, protects the general public well being by assuring the protection, effectiveness, and safety of human and veterinary medication, vaccines and different organic merchandise for human use, and medical units. The company is also accountable for the protection and safety of our nation’s meals provide, cosmetics, dietary dietary supplements, merchandise that give off digital radiation, and for regulating tobacco merchandise.


Please enter your comment!
Please enter your name here